六种中成药治疗糖尿病前期血脂异常的系统综述与网状Meta分析
该系统综述与网状Meta分析纳入27项随机对照试验共2227例糖尿病前期患者,比较指南推荐的6种中成药调脂的疗效与安全性。与单纯生活方式干预相比,金芪+生活方式干预、参芪+生活方式干预可显著降低甘油三酯和总胆固醇,参芪+生活方式干预在提高高密度脂蛋白胆固醇方面也有效,金利达+生活方式干预可降低低密度脂蛋白胆固醇。
要点
- 金芪+生活方式干预和参芪+生活方式干预可显著降低糖尿病前期患者甘油三酯和总胆固醇。
- 参芪+生活方式干预在提高高密度脂蛋白胆固醇方面效果最显著。
- 金利达+生活方式干预可降低低密度脂蛋白胆固醇但效果相对较弱。
核心结论
- 对于糖尿病前期患者,金芪和参芪联合生活方式干预与甘油三酯和总胆固醇的显著降低相关,其中参芪+生活方式干预效果最显著。
- 金利达+生活方式干预在降低低密度脂蛋白胆固醇方面效果相对最弱。
研究设计与样本
- 系统检索多个数据库中6种中成药治疗糖尿病前期的随机对照试验。
- 使用Review Manager 5.3和Cochrane协作系统评价员手册评估偏倚风险。
- 采用STATA 15.0基于频率统计模型进行网状Meta分析。
- 共纳入27项研究,涉及2227例患者。
主要发现
- 与生活方式干预相比,参芪+生活方式干预降低甘油三酯[SMD -0.49(95%CI:-0.85,-0.12)]和总胆固醇[SMD -0.51(95%CI:-0.86,-0.17)]有统计学意义。
- 与生活方式干预相比,金芪+生活方式干预降低甘油三酯[SMD -0.44(95%CI:-0.81,-0.06)]和总胆固醇[SMD -0.44(95%CI:-0.80,-0.08)]有统计学意义。
- 与生活方式干预相比,金利达+生活方式干预降低低密度脂蛋白胆固醇[SMD -0.31(95%CI:-0.59,-0.04)]有统计学意义。
- 与生活方式干预相比,参芪+生活方式干预[SMD 0.29(95%CI:0.06,0.51)]和金芪+生活方式干预[SMD 0.16(95%CI:0.01,0.31)]提高高密度脂蛋白胆固醇有统计学意义。
临床怎么用
- 在糖尿病前期血脂异常患者中,可考虑在生活方式干预基础上联合金芪或参芪以改善甘油三酯和总胆固醇。
- 若需提高高密度脂蛋白胆固醇,参芪联合生活方式干预可能更优。
- 金利达联合生活方式干预对低密度脂蛋白胆固醇有降低作用,但效应相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the clinical efficacy and safety of SIX Traditional Chinese Patent Medicines (TCPM) recommended by guidelines in improving lipids for patients with prediabetes by network meta-analysis. Methods: Randomized controlled trials of 6 TCPM in the treatment of prediabetes were searched systematically in various databases. After extracting effective data, the risk of bias was assessed using Review Manager 5.3 and Cochrane Collaboration Systems Evaluator's Manual. Network meta-analysis was performed using STATA 15.0 based on the frequency statistical model. The effect size and credibility of the evidence for the intervention were summarized based on a minimal contextualized framework. Results: A total of 27 studies involving 2,227 patients were included. Compared with lifestyle modification (LM), Shenqi + LM [SMD -0.49 (95% CI: -0.85, -0.12)] and Jinqi + LM [SMD -0.44 (95% CI: -0.81, -0.06)] showed statistically significant effect in lowering TG, Shenqi + LM [SMD -0.51 (95%CI: -0.86, -0.17)] and Jinqi + LM [SMD -0.44 (95%CI: -0.80, -0.08)] in lowering TC, Jinlida + LM [SMD -0.31 (95%CI: -0.59, -0.04)] in lowering LDL-C, Shenqi + LM [SMD 0.29 (95%CI: 0.06, 0.51)] and Jinqi + LM [SMD 0.16 (95%CI: 0.01, 0.31)] in increasing HDL-C. Conclusion: For patients with prediabetes, Traditional Chinese patent medicine Jinqi and Shenqi combined with lifestyle modification were associated with a significant reduction in TG and TC, while Shenqi + LM was among the most effective. Jinlida + LM was among the least effective. Systematic Review Registration: https://clinicaltrials.gov/, identifier PROSPERO(CRD42021279332).
引用
- Jiang L, Wang S, Zhao J, et al. Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis. Front Pharmacol. 2022. PMID: 36105194. doi:10.3389/fphar.2022.942563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。